Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Page 1
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.
Lancet. 2024 Sep 28;404(10459):1227-1239. doi: 10.1016/S0140-6736(24)01653-2. Epub 2024 Sep 15.
Lancet. 2024.
PMID: 39293462
Clinical Trial.
177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot.
Mateo J, Zurita AJ.
Mateo J, et al.
Lancet. 2024 Sep 28;404(10459):1174-1176. doi: 10.1016/S0140-6736(24)01919-6. Epub 2024 Sep 15.
Lancet. 2024.
PMID: 39293463
No abstract available.
Item in Clipboard
Cite
Cite